Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats1

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 3, 1996, Pages 1444-1453

  Song, Jianben ^a   Standley, Paul R ^a,b   Zhang, Feng ^a   Joshi, Darius ^a   Gappy, Saib ^a   Sowers, James R ^a,b   Ram, Jeffrey L ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CALCIUM CHANNEL; TAMOXIFEN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; CALCIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MEMBRANE POTENTIALS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; TAMOXIFEN;

EID: 0030439246     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. BATRA, S.: Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes. Cancer Chemother. Pharmacol. 26: 310-312, 1990.
2. BRATHERTON, D. G., BROWN, C. H., BUCHANAN, R., HALL, V., PILLERS, E. M. K., WHEELER, T. K. AND WILLIAMS, C. J.: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br. J. Cancer 50: 199-205, 1984.
3. COULDWELL, W. T., WEISS, M. H., DEGIORGIO, C. M., WEINER, L. P., HINTON, D. R., EHRESMANN, G. R., CONTI, P. S. AND APUZZO, M. L. J.: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-490, 1993.
4. DRISKA, S. P. AND PORTER, R.: Isolation of smooth muscle cells from swine carotid artery by digestion with papain. Am. J. Physiol. 251: C474-C481, 1986.
5. Early Breast Cancer Trialiats' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy in early breast cancer: An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 319: 1681-1692, 1988.
6. EPSTEIN, M.: Calcium antagonists in the management of hypertension. In Calcium Antagonists in Clinical Medicine, ed. by M. Epstein, pp. 213-230, Hanley & Belfus, Inc., Philadelphia, PA, 1992.
7. FANIDI, A., AHNADI, C., FAYARD, J. M., PAGEAUX, J. F. AND LAUGIER, C.: Opposite regulation of cAMP concentration in the quail oviduct and the mouse uterus by tamoxifen. Correlation with estrogen-antagonist and eatrogen-agonist activity. J, Steroid Biochem. Molec. Biol. 41: 571-577, 1992.
8. FURMAN, E., RUSHKIN, E., MARGALIT, R., BENDEL, P. AND DEGANI, H.: Tamoxifen induced changes in MCF7 human breast cancer: In vitro and in vivo studies using nuclear magnetic resonance spectroscopy and imaging. J. Steroid Biochem. Mol. Biol. 43: 189-195, 1992.
9. FURSPAN, P. B. AND WEBB, R. C.: Potassium channels and vascular reactivity in genetically hypertensive rats. Hypertension 15: 687-691, 1990.
10. GANITKEVICH, V. YA. AND ISENBERG, G.: Contribution of two types of calcium channels to membrane conductance of single myocytes from guinea-pig coronary artery. J. Physiol. 426: 19-42, 1990.
11. GRAINGER, D. J., WEISSBERG, P. L. AND METCALFE, J. C.: Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor B. Biochem. J. 294: 109-112, 1993.
12. GUPTA, V., KAMATH, N., TKALCEVIC, G. T. AND SINGH, S. V.: Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. Biochem. Pharmacol. 47: 1701-1704, 1994.
13. HARAN, E. F., MARETZEK, A. F., GOLDBERG, I., HOROWITZ, A. AND DEGANI, H.: Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res. 21: 5511-5514, 1994.
14. KEMP, J. V., ADAM, H. K., WAKELING, A. E. AND SLATER, R.: Identification and biological activity of tamoxifen metabolites in human serum. Biochem. Pharmacol. 32: 2045-2052, 1983.
15. LAM, P. H.-Y.: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Commun. 118: 27-32, 1984.
16. LAZO, J. S., SCHWARTZ, P. E., MACLUSKY, M. J., LABAREE, D. C. AND EISENFELD, A. J.: Antiproliferative actions of tamoxifen of human ovarian carcinomas in vitro. Cancer Res. 44: 2266-2271, 1984.
17. LIEN, E. A., SOLHEIM, E. AND UELAND, P. M.: Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Research 51: 4837-4844, 1991.
18. LIPTON, A.: The anti-oestrogen tamoxifen is a calcium antagonist in perfused rat mesentery. Cancer Chemother. Pharmacol. 20: 125-127, 1987.
19. 2+-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Research 50: 2753-2758, 1990.
20. LYMAN S. D. AND JORDAN, V. C.: Metabolism of nonsteroidal antiestrogens. In Estrogen/Antiestrogen Action and Breast Cancer Therapy, ed. by V. C. Jordan, pp. 191-219, University of Wisconsin Press, Madison, WI, 1986.
21. MCCARRON, J. G., MCGEOWN, J. G., REAEDON, S., IKEBE, M., FAY, F. S. AND WALSH JR., J. V.: Calcium-dependent enhancement of calcium current in smooth muscle by calmodulin-dependent protein kinase II. Nature 357: 74-77, 1992.
22. O'BRIAN, C. A., LISKAMP, R. M., SOLOMON, D. H. AND WEINSTEIN, I. B.: Inhibition of protein kinase C by tamoxifen. Cancer Res. 47: 70-74, 1985.
23. RAM, J. L., STANDLEY, P. R. AND SOWERS, J. R.: Calcium function in vascular smooth muscle and its relationship to hypertension. In Calcium Antagonists in Clinical Medicine, ed. by M. Epstein, pp. 29-48, Hanley & Belfus, Inc., Philadelphia, PA, 1992.
24. RAVI, J., MANTZOROS, C. S., PRABHU, A. S., RAM, J. L. AND SOWERS, J. R.: In vitro relaxation of phenylephrine- and angiotensin II-contracted aortic rings by β-estradiol. Am. J. Hypertens. 7: 1065-1069, 1994.
25. ROCHEFORT, H., GARCIA, M. AND BORGNA, J. L.: Absence of correlation between antioestrogenic activity and binding affinity for the oestrogen receptor. Biochem. Biophys. Res. Commun. 88: 351-357, 1979.
26. RUTQVIST, L. E. AND MATTSSON, A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J. Natl. Cancer Inst. 85: 1398-1406, 1993.
27. SIMPSON, L. L., ZHANG, F., STANDLEY, P. R., RAM, J. L., WEIR, M. R. AND SOWERS, J. R.: Antiproliferative effects of verapamil enantiomers on vascular smooth muscle cells. J. Vasc. Med. Biol. 5: 46-53, 1994.
28. STANDLEY, P. R., ZHANG, F., RAM, J. L., ZEMEL, M. B. AND SOWERS, J. R.: Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle. J. Clin. Invest. 88: 1230-1236, 1991.
29. TRUMP D. L., SMITH, D. C., ELLIS, P. G., ROGERS, M. P., SCHOLD, S. C., WINER, E. P., PANELLA, T. J., JORDAN, V. C. AND FINE, R. L.: High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J. Natl. Cancer Inst. 23: 1811-1816, 1992.
30. WALSH, M. P.: Calmodulin and the regulation of smooth muscle contraction. Mole. Cell. Biochem. 135: 21-41, 1994.
31. Ca channels through a cGMP-dependent mechanism. Circ. Res. 77: 936-942, 1995.
32. WISEMAN, H., QUINN, P. AND HALLIWELL, B.: Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions? FEBS Lett. 330: 53-56, 1993.
33. 2+ currents in A7r5 vascular smooth muscle cell line. Am. J. Physiol. 266: C975-C980, 1994a.
34. ZHANG, F., SOWERS, J. R., RAM, J. L., STANDLEY, P. R. AND PECLER, J. D.: Effects of pioglitazone on L-type calcium channels in vascular smooth muscle. Hypertension 24: 170-175, 1994b.